or Try an Advanced Search...

    Technical Analysis for ENTX - Entera Bio Ltd.

    Grade Last Price % Change Price Change
    B 2.25 -2.60% -0.06
    ENTX closed down 2.6 percent on Friday, May 31, 2024, on 8 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Down
    Historical ENTX trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Inside Day Range Contraction 0.00%
    Fell Below 20 DMA Bearish -2.60%
    50 DMA Support Bullish -2.60%
    Gapped Down Weakness -2.60%
    Lower Bollinger Band Touch Weakness -2.60%
    Crossed Above 20 DMA Bullish -7.41%
    Wide Bands Range Expansion 0.00%
    NR7 Range Contraction -3.02%
    Older End-of-Day Signals for ENTX ...

       Recent Intraday Alerts

    Alert Time
    Up 1% 2 days ago
    20 DMA Support 3 days ago
    10 DMA Support 3 days ago
    50 DMA Support 3 days ago
    Down 5% 3 days ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    ENTX Chart by TradingView
    Basic chart:

    Profile

    Entera Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in orphan indications and other areas with significant unmet medical need. The Company is initially applying its technology to develop an oral formulation of parathyroid hormone (PTH) for hypoparathyroidism (EB612) and osteoporosis (EB613).
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Endocrine System Hormones Thyroid Osteoporosis Molecule Therapeutics Glands Hypoparathyroidism Parathyroid Hormone

    Is ENTX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 16 Vanda (VNDA) Rises on Positive Data From Motion Sickness Study
    May 16 Are Medical Stocks Lagging Entera Bio (ENTX) This Year?
    May 15 Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member
    Apr 26 Entera Bio Ltd. (ENTX) Stock Slides as Market Rises: Facts to Know Before You Trade
    Apr 18 Why the Market Dipped But Entera Bio Ltd. (ENTX) Gained Today
    Apr 12 Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?
    Apr 9 Here's Why You Should Invest in Entera Bio (ENTX) Stock Now
    Apr 8 Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research
    Mar 24 12 Best Biotech Penny Stocks to Invest In
    Mar 23 We Think Entera Bio (NASDAQ:ENTX) Can Afford To Drive Business Growth
    See more ENTX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.35
    52 Week Low 0.52
    Average Volume 265,044
    200-Day Moving Average 1.15
    50-Day Moving Average 2.17
    20-Day Moving Average 2.40
    10-Day Moving Average 2.34
    Average True Range 0.23
    RSI (14) 48.45
    ADX 15.83
    +DI 19.10
    -DI 22.33
    Chandelier Exit (Long, 3 ATRs) 2.08
    Chandelier Exit (Short, 3 ATRs) 2.59
    Upper Bollinger Bands 2.63
    Lower Bollinger Band 2.16
    Percent B (%b) 0.19
    BandWidth 19.49
    MACD Line 0.04
    MACD Signal Line 0.08
    MACD Histogram -0.0354
    Fundamentals Value
    Market Cap 79.82 Million
    Num Shares 35.5 Million
    EPS -0.34
    Price-to-Earnings (P/E) Ratio -6.62
    Price-to-Sales 2280.62
    Price-to-Book 5.12
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.39
    Resistance 3 (R3) 2.40 2.37 2.36
    Resistance 2 (R2) 2.37 2.34 2.36 2.35
    Resistance 1 (R1) 2.31 2.31 2.30 2.30 2.35
    Pivot Point 2.28 2.28 2.27 2.27 2.28
    Support 1 (S1) 2.22 2.25 2.21 2.21 2.15
    Support 2 (S2) 2.19 2.22 2.18 2.15
    Support 3 (S3) 2.13 2.19 2.14
    Support 4 (S4) 2.12